Combo Drug Treatment for Type 2 Diabetes Remains Effective After Two Years

November 30, 2020

A drug combo of dapagliflozin and exenatide continues to stay effective at controlling the progression of type 2 diabetes, without loss of effect, after two years of continual use, according to a study recently published in Diabetes Care. In a multi-center double-blind, phase 3, randomized controlled trial, a total of 695 adults whose type 2 […]

To view the full Member Resource, please Log in

TOPICS IN THIS ARTICLE:

←Endocrine Society and Pediatric Endocrine Society Partner on Transgender Advocacy

Lying in Wait: The Hidden Threat of Primary Aldosteronism→

View Archives

Join the Global Movement Advancing Endocrine Science and Medicine

Become a part of a community of 18,000-plus endocrine investigators and clinicians who conduct research and provide quality patient care in more than 100 countries. Advance your career and the field of endocrinology through our many educational, leadership and advocacy opportunities.

Join Today